A multiparametric magnetic resonance imaging‐based risk model to determine the risk of significant prostate cancer prior to biopsy

Abstract

Individualised risk assessment of significant prostate cancer using a predictive model that incorporates mpMRI PIRADS score and clinical data allows a considerable reduction in unnecessary biopsies and reduction of the risk of over-detection of insignificant prostate cancer at the cost of a very small increase in the number of significant cancers missed.